

An Oral, Selective, and Potent EGFR Mutant Protein Degradator for the Treatment of NSCLC

J2H Biotech



ONCOLOGY	Non-Clinical
Product Type	Targeted protein degradation (TPD Drug)
Indication	EGFR mutated NSCLC
Target	<ul style="list-style-type: none"> • NSCLC with EGFR single, double and triple mutation • Osimertinib-resistant EGFR mutated NSCLC (C797S double and triple mutation)
MoA (Mechanism of Action)	EGFR mutant targeted protein degrader
Competitiveness	<ul style="list-style-type: none"> • Wide therapeutic coverage of EGFR single, double, and triple mutations • High selectivity towards wild-type EGFR (↓ side effect) • Overcomes drug resistance mechanisms to traditional targeted therapies • Oral formulation with excellent bioavailability in 3 animal models
Development Stage	Non-Clinical
Route of Administration	Oral